Women’s Brains Are a $1 Trillion Opportunity

Nowhere is the cost of ignoring women’s health more visible or more correctable than in the brain. Closing the women’s health gap could add $1 trillion in annual incremental GDP to the global economy. That figure should reframe how every boardroom and budget office thinks about women’s health. 

Women’s health is a macroeconomic opportunity we have ignored. Last month, the Department of Health and Human Services convened its inaugural National Conference on Women’s Health. It is time to treat this issue with the urgency and rigor it deserves.

Women live longer than men but spend roughly 25% more of their lives in poor health. The consequences show up in workforce productivity, family finances, and the long-term sustainability of healthcare systems. When we trace those costs to their source, the brain appears at the center, and therefore should be the entry point to the highest-impact solutions.

Breaking the cycle requires action in three places simultaneously. Research funders need to mandate sex-disaggregated data and fund women-focused trials for brain disease. Employers need to add menopause benefits and cognitive health support to standard benefits packages. And policymakers need to recognize women’s brain health as a core input to labor force productivity and healthcare system solvency.

The evidence for each is substantial.

The Alzheimer’s Burden Falls on Women Twice

Nearly two-thirds of Americans living with Alzheimer’s are women. More than 60% of Alzheimer’s and dementia caregivers are also women, often in their prime working years. Women often take on this caregiving role without pay. 

Dementia costs the United States approximately $781 billion per year, which includes $232 billion in medical and long-term care and $233 billion in unpaid caregiving labor. This caregiving represents 6.8 billion hours of work that never appears in GDP, but drains family savings, stalls careers, and removes experienced workers from the labor force. Families absorb roughly 70% of the total lifetime cost of dementia care.

This double burden—women having a higher lifetime risk of developing the disease, and being more likely to shoulder the caregiving when others do—is why Alzheimer’s functions as an economic drag. Beyond affecting individual health, it shapes the stability of families, the depths of labor pools, and the long-term viability of public healthcare spending.

The economic case for prevention is correspondingly large. Research from the Cutting Alzheimer’s Risk through Endocrinology initiative estimates that halving the lifetime risk of Alzheimer’s in women could save the U.S. alone $4.56 trillion.

The Productivity Drain We Have Accepted

Alzheimer’s is the most visible expression of a broader pattern. Women of working age face disproportionately high rates of depression, anxiety, and the cognitive and emotional effects of menopause. These conditions show up at work as reduced engagement, absenteeism, and turnover. Reducing the global burden of depression alone could contribute up to $230 billion in GDP growth through productivity gains. Reducing anxiety disorders could add $169 billion more.

Menopause deserves particular attention. It is a neurological event, not just a reproductive one: the menopause transition is associated with measurable alterations in brain structure, connectivity, and energy metabolism, which may influence cognition and mood. Untreated menopause symptoms cost the U.S. economy an estimated $26.6 billion annually. Yet only 21% of employers offer menopause-specific benefits. For employers, the math is unforgiving: replacing a single employee costs 40% to 200% of their annual salary. When brain health needs go unaddressed, organizations pay twice: first in absenteeism, then in churn. 

Why the Market Hasn’t Fixed This

The underinvestment in women’s brain health is the product of a self-reinforcing cycle. Men’s health has long served as the default baseline for medical research and clinical trials, leaving an evidence gap for women that gets misread, by investors and funders, as investment risk. Under-researched means underfunded and underfunded means slower progress. Slower progress appears to validate the original decision not to invest.

Read more: Clinical Trials Have a Gender Problem

Only 6% of private healthcare investment is focused on women, the majority concentrated in reproductive health, maternal care, and cancer. These are important areas. But major conditions that affect women uniquely and disproportionately, including Alzheimer’s and menopause, remain chronically underfunded. Addressing just four underserved therapeutic areas for women in the U.S. could unlock a market opportunity exceeding $100 billion by 2030.  

The returns on these investments are measurable and waiting. A $1 trillion opportunity does not persist indefinitely because the market missed it; it persists because the market is not organized to see it. 

This is a correctable problem if we treat it with the urgency and rigor we apply to any other high-return asset.